STAT+: Roche to buy PathAI for $750 million
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Roche agreed to pay $750 million upfront to acquire PathAI, a Boston‑based AI pathology startup.
- Roche will pay up to $300 million in milestone‑based payments if PathAI meets specified performance targets.
- Roche expects the acquisition to close in the second half of 2026.
- Andy Beck, PathAI’s CEO, said the partnership will enable AI‑powered diagnostics to reach patients worldwide at unprecedented scale and speed.
Why it matters: Roche’s $750M acquisition and up to $300M milestone payout give it immediate AI‑diagnostic assets, while patients stand to receive faster, more accurate pathology services worldwide.
Ask SkimNews
